TNF-α antagonists for the treatment of Crohn's disease

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 615-622

  Kam, Lori Y ^a,b   Targan, Stephan R ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Inflammatory Bowel Disease Center   (United States)

Author keywords

Chimeric antibody; Crohn's disease; Cytokines; Inflammatory bowel disease; Infliximab; TNF a

Indexed keywords

DRUG DERIVATIVE; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CROHN DISEASE; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034189490     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.615     Document Type: Article

References (22)

1. VAN DEVENTER SJH: Tumour necrosis factor and Crohn's disease. Gwr(1997) 40:443-448. • Comprehensive review of the role of TNF in CD.
2. KNIGHT DM, HAN T, LE J et al.: Construction and initial characterization of a mouse-human chimcric anti-TNF antibody. Mol. Immitnol. (1993) 30:12443-12453-• Initial report of the structure and characteristics of infliximab.
3. DERKX B, TAMINIAU J, RADEMA S et al.: Tumournccrosis-factor antibody treatment in Crohn's disease. lancet (1993) 342:173-174. • First report of anti-TNF chimeric antibody treatment in a patient with refractory CD.
4. VAN DULLEMAN HM, VAN DEVENTER SJH, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (CA2). Gastmenterology (.1995) 109:129-135. • Open labelled study of CA2 in 10 patients with refractory CD.
5. TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al: A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor a for Crohn's discase. N. Engl.J. Med. ( 1997) 337:1029-1035. • First multi-centre, placebo-controlled, double-blind clinical trial demonstrating efficacy of CA2 in patients with refractory CD.
6. PRESENT DH, RUTGEERTS P, TARGAN S. et ah InfJiximab for the treatment of fistulas in patients with Crohn's disease. N. Engl.J. Med. (1999) 340:1398-1405. • Multi-centre, placebo-controlled, randomised trial of Infliximab for patients with fistulising CD.
7. RUTGEERTS P, D'HAENS G, TARGAN S etal.: Efficacy and safety of retreatmcnt with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroentemlogy (1999) 117:761-769. •Efficacy of maintenance therapy with infliximab for patients with CD.
8. CENTOCOR, INC.: Remicade Product Insert.
9. BicKSTON sj, LICHTENSTEIN"GR, ARSENEQU KO et ai.-. The relationship between Infliximab treatment and lymphoma in Crohn's disease. Gastmenterology (1999) 117:1433-1437.
10. SANDBORN WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflam. Bowel Dis. (1999) 5:119-133.
11. TARGAN SR: Personal communication regarding review of cases demonstrating delayed hypersensitivity reactions observed in clinical practice.
12. STACK WA, MANN SD, ROY AJ et al.: Randomised controlled trial of CDP571 antibody to tumor necrosis factor-a in Crohn's disease, lancet (1997) 349:521-524. • First randomised, placebo-controlled, double-blind study of CDP571 in patients with CD.
13. CELLTECH CHIROSCIENCE: Press Release (11 November 1999).
14. VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastmenterology (1999) 117:1278-1287. •Initial pilot study showing efficacy of thalidomide treatment in refractory, steroid dependent CD.
15. EHRENPREIS ED, KÄME SV, COHEN LD étal: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271-1277. • Initial open label trial of thalidomide in patients with refractory CD.
16. MORELAND LW, MARGOLIES G, HECH LW et al.: Kecombinant soluablc tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory reheumatoid arthritis. J. Rheumatol. (1990 23:1849-55. • Double-blind single centre study of the efficacy of recombinant human sTNFr fusion protein (p80) in patients with RA.
17. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (;75)-Fc fusion protein. M Engl.J. Med. (1997) 337:141-147. • Multi-centre, randomised, double-blind, placebo-controlled trial of TNF-r:Fc in patients with RA.
18. WEINBLATT ME, DREMER JM, BANKHURST AD et al.: A trial of ctancrccpt, a recombinant tumorc necrosis factor recepton fc fusion protein, in patients with rheumatoid arthritis receiving methotrcxate. N. Engl.J. Med. ( 1999) 340:253-259. • Randomised, placebo-controlled trial demonstrating increased efficacy of etanercept in combination with MTX therapy in patients with RA.
19. MAIN1RN, BREEDVELD FC, KALDEN JR etal: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552-1563. • Clinical trial showing decreased HACA response in patients receiving concurrent MTX and multiple doses of infliximab versus infliximab alone.
20. HANAUER SB COHEN RD, BECKER RV et al.: Advances in the management of Crohn's disease: economic and clinical potential of Infliximab. Clin. Tber. (1998) 20:1009-1028. • Economic assessment of the cost of CD treatment.
21. HAY JW, HAY AR: Inflammatory bowel disease: costs-of illness.J. Clin. Gastroenterol. (1992) 14:309-317. • Economic assessment of the cost of CD treatment.
22. Drug Topics Red Book. Medical Economics Co., Inc., Montvale, New Jersey, USA (1999):523-564.